Drugmaker Novo Nordisk's third-quarter operating profit slightly lags forecast

COPENHAGEN (Reuters) - Novo Nordisk posted third-quarter operating profit a touch below expectations on Friday but nudged up its sales outlook for this year on the back of its new drugs for type 2 diabetes and obesity.The world's largest maker of diabetes drugs posted a quarterly operating profit of 12.9 billion Danish crowns ($1.93 billion), slightly below an average 13.1 billion crowns forecast in a Refinitiv poll of analysts.